Publication:
Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma

Thumbnail Image
Files
Sato-34-1365-1375-2019.pdf(2.39 MB)
Date
2019
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Sato, Ai ; Miki, Yasuhiro ; Takagi, Kiyoshi ; Yoshimura, Ayano ; Hara, Mizuki ; Ishida, Takanori ; Sasano, Hironobu ; Suzuki, Takashi
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-130
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background. Cytochrome c1 (CYC1) is a heme-containing subunit of mitochondria complex III and is mainly involved in cellular energy production. A recent study has demonstrated that CYC1 was overexpressed in breast carcinoma tissues and induced proliferation, migration and invasion of estrogen receptor (ER)-negative breast carcinoma cells. However, the clinical significance of CYC1 protein remains largely unclear in invasive breast carcinoma, and biological functions of CYC1 have not been reported in ER- positive breast carcinoma cells. Materials and methods. We immunolocalized CYC1 in 172 invasive breast carcinomas and evaluated its clinical significance according to the ER-status. Subsequently, we examined the effects of CYC1 on proliferation, glycolysis and chemosensitivity to paclitaxel, which is one of the most common chemotherapeutic agents in breast cancer, in ER-positive breast carcinoma cells (MCF7 and T47D). Results. CYC1 immunoreactivity was detected in 47% of ER-positive cases and 30% of ER-negative cases. Immunohistochemical CYC1 status was inversely associated with Ki67 in ER-positive cases, and it was a significantly favorable prognostic factor for both disease-free and breast cancer-specific survival of the patients. On the other hand, no significant association was detected between CYC1 status and clinico- pathological factors in ER-negative cases. In in vitro experiments, MCF7 and T47D cells transfected specific siRNA for CYC1 significantly increased cell proliferation activity, L-lactate production and cell viability after paclitaxel treatment. Conclusion. These results suggest that CYC1 inhibits cell proliferation, glycolytic activity and increases chemosensitivity to paclitaxel in ER-positive breast carcinoma cells and that CYC1 status is a potent favorable prognostic factor in ER-positive breast cancer patients
publication.page.subject
Breast Neoplasms , Chemosensitivity , Cytochrome c1 , Estrogen Receptor , Prognosis
Citation
Histology and Histopathology Vol. 34, nº 12 (2019)
URI
http://hdl.handle.net/10201/124948
item.page.embargo
Collections
Histology and histopathology Vol.34,nº12 (2019)
Ir a Estadísticas